A Phase 2 interventional study of Doravirine, Tenofovir, Lamivudine - Blinded and Doravirine, Tenofovir, Lamivudine - Open-Label in HIV-1 and Central Nervous System, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate a switch from fixed dose combination (FDC) treatment with ATRIPLA\^TM for 12 weeks prior to screening to FDC treatment with Doravirine, Tenofovir, Lamivudine (MK-1439A) in virologically-suppressed, human immunodeficiency virus type 1 (HIV-1)-infected participants. The primary hypothesis is that switching from ATRIPLA\^TM to Doravirine, Tenofovir, Lamivudine results in a lower proportion of participants with at least one CNS toxicity of at least Grade 2 intensity at Week 12 than continuation of ATRIPLA\^TM treatment.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants on a baseline regimen of ATRIPLA™ for at least 12 weeks prior to screening will be switched to blinded doravirine, tenofovir, lamivudine orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for an additional 12 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 216 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 312 weeks.
Drug: Doravirine, Tenofovir, Lamivudine - Blinded · Drug: Doravirine, Tenofovir, Lamivudine - Open-Label · Drug: Placebo to ATRIPLA™
Participants will continue on their ongoing ATRIPLA™ regimen orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for 24 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 228 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 324 weeks.
Drug: Doravirine, Tenofovir, Lamivudine - Open-Label · Drug: ATRIPLA^TM · Drug: Placebo to Doravirine, Tenofovir, Lamivudine
A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period
Also known as: MK-1439A
A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.
Also known as: MK-1439A
A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period
A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period
Percentage of Participants With at Least One Central Nervous System (CNS) Toxicity of at Least Grade 2 Intensity at Week 12
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. Percentage of participants with at least one CNS toxicity of Grade 2 or higher were recorded, based on the last observation carried forward (LOCF) approach.
Time frame: Week 12
Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Week 4
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. Percentage of participants with at least one CNS toxicity of Grade 2 or higher were recorded, based on the last observation carried forward (LOCF) approach.
Time frame: Week 4
Change From Baseline in CNS Toxicity Score at Week 4
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A positive change from baseline score indicates worsening symptoms. A negative change from baseline score indicates improvement in symptoms.
Time frame: Baseline and Week 4
Change From Baseline in CNS Toxicity Score at Week 12
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A positive change from baseline score indicates worsening symptoms. A negative change from baseline score indicates improvement in symptoms.
Time frame: Baseline and Week 12
Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. For the Immediate Switch Group (ISG) time of switch was study Day 1, and week 24 post-switch was week 24. For the Delayed Switch Group (DSG) time of switch was study week 12, and week 24 post-switch was week 36.
Time frame: Baseline (time of switch) and 24 weeks post-switch
CNS Toxicity Scores at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A higher CNS score indicates worse symptoms. A positive change in CNS score indicates worsening symptoms. A negative change indicates improvement in symptoms. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.
Time frame: Baseline (time of switch) and 24 weeks post-switch
Change From Baseline in Fasting Lipids at Week 12
Blood was collected under fasting conditions on Day 1 and on week 12 in order to determine the concentration of the following lipids: low-density lipoprotein (LDL) cholesterol; Non high-density lipoprotein (HDL) cholesterol; cholesterol; HDL cholesterol; and triglyceride.
Time frame: Baseline (study Day 1) and study week 12
Change in Fasting Lipids Between Time of Switch and Week 24 Post-switch for the Combined Treatment Groups
Blood was collected under fasting conditions at time of switch and 24 weeks post-switch in order to determine the change from baseline of the following lipids: low-density lipoprotein (LDL) cholesterol; Non high-density lipoprotein (HDL) cholesterol; cholesterol; HDL cholesterol; and triglyceride. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.
Time frame: Baseline (time of switch) and 24 weeks post-switch
Percentage of Participants With HIV-1 RNA <50 and <40 Copies/ml at Week 24 Post-switch for the Combined Treatment Groups
Blood was collected under fasting conditions at 24 weeks post-switch in order to determine the HIV-1 RNA. For the ISG week 24 post-switch was week 24. For the DSG week 24 post-switch was week 36.
Time frame: 24 weeks post-switch
Change From Time of Switch to Week 24 Post Switch in CD4 T-cell Count for the Combined Treatment Groups
Blood was collected at time of switch and at 24 weeks post-switch in order to determine the CD4 T-cell count. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.
Time frame: Baseline (time of switch) and 24 weeks post-switch
Number of Participants With One or More Adverse Events (AEs) Through Study Week 12
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
Time frame: Up to Week 12
Number of Participants With One or More Drug-related AEs Through Study Week 12
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was determined by the investigator to be related to the drug.
Time frame: Up to Week 12
Number of Participants With One or More Serious Adverse Events (SAEs) Through Study Week 12
A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose.
Time frame: Up to Week 12
Number of Participants With One or More Drug-related SAEs Through Study Week 12
A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. A drug-related SAE was determined by the investigator to be related to the drug.
Time frame: Up to Week 12
Number of Participants Who Discontinued Treatment Due to an AE Through Study Week 12
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
Time frame: Up to Week 12
Number of Participants With One or More AEs for the Combined Treatment Groups 24 Weeks After the Switch
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.
Time frame: 24 weeks post-switch
Number of Participants With One or More Drug-related AEs for the Combined Treatment Groups 24 Weeks After the Switch
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was determined by the investigator to be related to the drug. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.
Time frame: 24 weeks post-switch
Number of Participants With One or More SAEs for the Combined Treatment Groups 24 Weeks After the Switch
A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.
Time frame: 24 weeks post-switch
Number of Participants With One or More Drug-related SAEs for the Combined Treatment Groups 24 Weeks After the Switch
A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. A drug-related SAE was determined by the investigator to be related to the drug. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.
Time frame: 24 weeks post-switch
Number of Participants Who Discontinued Treatment Due to an AE for the Combined Treatment Groups 24 Weeks After the Switch
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.
Time frame: 24 weeks post-switch
| Milestone | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Started | 43 | 43 |
| Switched over to mk-1439a | 0 | 42 |
| Completed | 43 | 41 |
| Not completed | 0 | 2 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Started | 43 | 41 |
| Completed | 39 | 34 |
| Not completed | 4 | 7 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Pregnancy | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Availability of study drug locally | 1 | 1 |
| Withdrew: Adverse event | 0 | 2 |
| Milestone | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Started | 39 | 33 |
| Completed | 17 | 19 |
| Not completed | 22 | 14 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Availability of study drug locally | 18 | 13 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Pregnancy | 1 | 1 |
| Milestone | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Started | 17 | 19 |
| Completed | 10 | 8 |
| Not completed | 7 | 11 |
| Withdrew: Physician decision | 7 | 10 |
| Withdrew: Pregnancy | 0 | 1 |
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. Percentage of participants with at least one CNS toxicity of Grade 2 or higher were recorded, based on the last observation carried forward (LOCF) approach.
| Percentage of participants | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Percentage of Participants With at Least One Central Nervous System (CNS) Toxicity of at Least Grade 2 Intensity at Week 12 | 41.9 | 37.2 |
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. Percentage of participants with at least one CNS toxicity of Grade 2 or higher were recorded, based on the last observation carried forward (LOCF) approach.
| Percentage of participants | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Week 4 | 46.5 | 65.1 |
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A positive change from baseline score indicates worsening symptoms. A negative change from baseline score indicates improvement in symptoms.
| Percentage of maximum score | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Change From Baseline in CNS Toxicity Score at Week 4 | -17.6 (-23.4 to -11.8) | -15.6 (-22.0 to -9.2) |
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A positive change from baseline score indicates worsening symptoms. A negative change from baseline score indicates improvement in symptoms.
| Percentage of maximum score | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Change From Baseline in CNS Toxicity Score at Week 12 | -18.1 (-22.9 to -13.3) | -21.7 (-27.9 to -15.5) |
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. For the Immediate Switch Group (ISG) time of switch was study Day 1, and week 24 post-switch was week 24. For the Delayed Switch Group (DSG) time of switch was study week 12, and week 24 post-switch was week 36.
| Percentage of participants | Combined Treatment Groups: Time of Switch | Combined Treatment Groups: Week 24 Post-Switch |
|---|---|---|
| Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups | 68.6 | 30.2 |
A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A higher CNS score indicates worse symptoms. A positive change in CNS score indicates worsening symptoms. A negative change indicates improvement in symptoms. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.
| Percentage of maximum score | Combined Treatment Groups: Time of Switch | Combined Treatment Groups: Week 24 Post-Switch |
|---|---|---|
| CNS Toxicity Scores at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups | 24.2 (20.5 to 27.9) | 10.7 (8.7 to 12.8) |
Blood was collected under fasting conditions on Day 1 and on week 12 in order to determine the concentration of the following lipids: low-density lipoprotein (LDL) cholesterol; Non high-density lipoprotein (HDL) cholesterol; cholesterol; HDL cholesterol; and triglyceride.
| mg/dL | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| LDL Cholesterol | -10.78 ± 15.85 | -1.88 ± 14.88 |
| Non-HDL Cholesterol | -14.08 ± 17.17 | -0.37 ± 16.51 |
| Cholesterol | -22.14 ± 19.49 | 0.00 ± 18.04 |
| HDL Cholesterol | -8.05 ± 7.74 | 0.37 ± 7.91 |
| Triglyceride | -21.19 ± 43.37 | 7.10 ± 38.55 |
Blood was collected under fasting conditions at time of switch and 24 weeks post-switch in order to determine the change from baseline of the following lipids: low-density lipoprotein (LDL) cholesterol; Non high-density lipoprotein (HDL) cholesterol; cholesterol; HDL cholesterol; and triglyceride. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.
| mg/dL | Combined Treatment Groups |
|---|---|
| LDL Cholesterol | -10.97 ± 17.15 |
| Non-HDL Cholesterol | -13.18 ± 19.82 |
| Cholesterol | -20.91 ± 20.19 |
| HDL Cholesterol | -7.72 ± 9.53 |
| Triglyceride | -12.99 ± 46.61 |
Blood was collected under fasting conditions at 24 weeks post-switch in order to determine the HIV-1 RNA. For the ISG week 24 post-switch was week 24. For the DSG week 24 post-switch was week 36.
| Percentage of participants | Combined Treatment Groups |
|---|---|
| < 50 copies/mL | 95.3 (88.4 to 98.7) |
| < 40 copies/mL | 95.3 (88.4 to 98.7) |
Blood was collected at time of switch and at 24 weeks post-switch in order to determine the CD4 T-cell count. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.
| cells/mm^3 | Combined Treatment Groups |
|---|---|
| Change From Time of Switch to Week 24 Post Switch in CD4 T-cell Count for the Combined Treatment Groups | 70.4 (35.9 to 104.8) |
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
| Participants | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Number of Participants With One or More Adverse Events (AEs) Through Study Week 12 | 34 | 34 |
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was determined by the investigator to be related to the drug.
| Participants | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Number of Participants With One or More Drug-related AEs Through Study Week 12 | 14 | 9 |
A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose.
| Participants | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Number of Participants With One or More Serious Adverse Events (SAEs) Through Study Week 12 | 0 | 0 |
A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. A drug-related SAE was determined by the investigator to be related to the drug.
| Participants | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Number of Participants With One or More Drug-related SAEs Through Study Week 12 | 0 | 0 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
| Participants | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A |
|---|---|---|
| Number of Participants Who Discontinued Treatment Due to an AE Through Study Week 12 | 0 | 0 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.
| Participants | Combined Treatment Groups |
|---|---|
| Number of Participants With One or More AEs for the Combined Treatment Groups 24 Weeks After the Switch | 71 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was determined by the investigator to be related to the drug. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.
| Participants | Combined Treatment Groups |
|---|---|
| Number of Participants With One or More Drug-related AEs for the Combined Treatment Groups 24 Weeks After the Switch | 18 |
A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.
| Participants | Combined Treatment Groups |
|---|---|
| Number of Participants With One or More SAEs for the Combined Treatment Groups 24 Weeks After the Switch | 1 |
A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. A drug-related SAE was determined by the investigator to be related to the drug. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.
| Participants | Combined Treatment Groups |
|---|---|
| Number of Participants With One or More Drug-related SAEs for the Combined Treatment Groups 24 Weeks After the Switch | 0 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.
| Participants | Combined Treatment Groups |
|---|---|
| Number of Participants Who Discontinued Treatment Due to an AE for the Combined Treatment Groups 24 Weeks After the Switch | 0 |
Collected over Up to approximately 326 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immediate Switch to MK-1439A (Day 1 to Week 24) | 0/43 (0%) | 0/43 (0%) | 29/43 (67.4%) |
| Deferred Switch to MK-1439A (Day 1 to Week 12) | 0/43 (0%) | 0/43 (0%) | 25/43 (58.1%) |
| Deferred Switch to MK-1439A (Week 12-36) | 0/42 (0%) | 1/42 (2.4%) | 26/42 (61.9%) |
| Immediate Switch to MK-1439A EXT 1 (Week 24-120) | 0/43 (0%) | 6/43 (14%) | 31/43 (72.1%) |
| Deferred Switch to MK-1439A EXT 1 (Week 36-132) | 0/41 (0%) | 2/41 (4.9%) | 33/41 (80.5%) |
| Immediate Switch to MK-1439A EXT 2 (Week 120-216) | 0/39 (0%) | 3/39 (7.7%) | — |
| Deferred Switch to MK-1439A EXT 2 (Week 132-228) | 0/33 (0%) | 1/33 (3%) | — |
| Immediate Switch to MK-1439A EXT 3 (Week 216-312) | 0/17 (0%) | 2/17 (11.8%) | — |
| Deferred Switch to MK-1439A EXT 3 (Week 228-324) | 0/19 (0%) | 0/19 (0%) | — |
| Event | Immediate Switch to MK-1439A (Day 1 to Week 24) | Deferred Switch to MK-1439A (Day 1 to Week 12) | Deferred Switch to MK-1439A (Week 12-36) | Immediate Switch to MK-1439A EXT 1 (Week 24-120) | Deferred Switch to MK-1439A EXT 1 (Week 36-132) | Immediate Switch to MK-1439A EXT 2 (Week 120-216) | Deferred Switch to MK-1439A EXT 2 (Week 132-228) | Immediate Switch to MK-1439A EXT 3 (Week 216-312) | Deferred Switch to MK-1439A EXT 3 (Week 228-324) |
|---|---|---|---|---|---|---|---|---|---|
| Head injuryInjury, poisoning and procedural complications | 0/43 | 0/43 | 0/42 | 0/43 | 0/41 | 0/39 | 0/33 | 1/17 | 0/19 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/43 | 0/43 | 0/42 | 0/43 | 0/41 | 0/39 | 0/33 | 1/17 | 0/19 |
| CystoceleReproductive system and breast disorders | 0/43 | 0/43 | 0/42 | 0/43 | 0/41 | 1/39 | 0/33 | 1/17 | 0/19 |
| AppendicitisInfections and infestations | 0/43 | 0/43 | 0/42 | 0/43 | 0/41 | 0/39 | 1/33 | 0/17 | 0/19 |
| Wound sepsisInfections and infestations | 0/43 | 0/43 | 0/42 | 0/43 | 0/41 | 0/39 | 1/33 | 0/17 | 0/19 |
| Stab woundInjury, poisoning and procedural complications | 0/43 | 0/43 | 0/42 | 0/43 | 0/41 | 1/39 | 0/33 | 0/17 | 0/19 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/43 | 0/43 | 0/42 | 1/43 | 0/41 | 1/39 | 0/33 | 0/17 | 0/19 |
| Pneumonia haemophilusInfections and infestations | 0/43 | 0/43 | 0/42 | 0/43 | 1/41 | 0/39 | 0/33 | 0/17 | 0/19 |
| Suicide attemptPsychiatric disorders | 0/43 | 0/43 | 0/42 | 0/43 | 1/41 | 0/39 | 0/33 | 0/17 | 0/19 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/43 | 0/43 | 1/42 | 0/43 | 0/41 | 0/39 | 0/33 | 0/17 | 0/19 |
| Event | Immediate Switch to MK-1439A (Day 1 to Week 24) | Deferred Switch to MK-1439A (Day 1 to Week 12) | Deferred Switch to MK-1439A (Week 12-36) | Immediate Switch to MK-1439A EXT 1 (Week 24-120) | Deferred Switch to MK-1439A EXT 1 (Week 36-132) | Immediate Switch to MK-1439A EXT 2 (Week 120-216) | Deferred Switch to MK-1439A EXT 2 (Week 132-228) | Immediate Switch to MK-1439A EXT 3 (Week 216-312) | Deferred Switch to MK-1439A EXT 3 (Week 228-324) |
|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 11/43 | 7/43 | 3/42 | 8/43 | 14/41 | — | — | — | — |
| AnxietyPsychiatric disorders | 2/43 | 2/43 | 7/42 | 7/43 | 11/41 | — | — | — | — |
| InsomniaPsychiatric disorders | 8/43 | 7/43 | 6/42 | 5/43 | 10/41 | — | — | — | — |
| SomnolenceNervous system disorders | 6/43 | 3/43 | 5/42 | 9/43 | 7/41 | — | — | — | — |
| DepressionPsychiatric disorders | 3/43 | 1/43 | 4/42 | 5/43 | 8/41 | — | — | — | — |
| Upper respiratory tract infectionInfections and infestations | 4/43 | 6/43 | 2/42 | 4/43 | 7/41 | — | — | — | — |
| AggressionPsychiatric disorders | 3/43 | 2/43 | 2/42 | 4/43 | 7/41 | — | — | — | — |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/43 | 1/43 | 2/42 | 4/43 | 3/41 | — | — | — | — |
| DizzinessNervous system disorders | 7/43 | 5/43 | 5/42 | 5/43 | 5/41 | — | — | — | — |
| Confusional statePsychiatric disorders | 1/43 | 1/43 | 3/42 | 6/43 | 6/41 | — | — | — | — |
| Age, Continuous(Years) | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A | Total |
|---|---|---|---|
| Mean | 41.8 ± 11.9 | 41.6 ± 11.2 | 41.7 ± 11.5 |
| Sex: Female, Male(Participants) | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A | Total |
|---|---|---|---|
| Female | 19 | 17 | 36 |
| Male | 24 | 26 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 5 |
| Not Hispanic or Latino | 39 | 42 | 81 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 25 | 23 | 48 |
| White | 12 | 19 | 31 |
| More than one race | 3 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| CNS Toxicity Percentage Of Maximum Score(Percentage of maximum score) | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A | Total |
|---|---|---|---|
| Mean | 32.9 ± 16.5 | 37.1 ± 19.0 | 35.0 ± 17.8 |
| Fasting Lipids(mg/dL) | Immediate Switch to MK-1439A | Deferred Switch to MK-1439A | Total |
|---|---|---|---|
| LDL Cholesterol | 98.67 ± 35.28 | 99.54 ± 33.57 | 99.13 ± 34.15 |
| Non-HDL Cholesterol | 118.73 ± 36.93 | 117.76 ± 37.83 | 118.22 ± 37.16 |
| Cholesterol | 178.11 ± 36.39 | 173.02 ± 36.62 | 175.44 ± 36.37 |
| HDL Cholesterol | 59.38 ± 14.58 | 55.27 ± 14.00 | 57.22 ± 14.34 |
| Triglyceride | 107.49 ± 65.64 | 91.39 ± 39.43 | 99.03 ± 53.73 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2016 to primary completion in Aug 2018, 29 months.
Results were first posted in Aug 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doravirine